Literature DB >> 20447462

HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.

Ann Woolfrey1, Stephanie J Lee, Ted A Gooley, Mari Malkki, Paul J Martin, John M Pagel, John A Hansen, Effie Petersdorf.   

Abstract

To determine whether the risks of allogeneic transplantation are different when the donor is a fully matched unrelated donor (MUD; based on 10/10 HLA alleles) compared to an HLA-identical sibling, we performed a retrospective analysis of 1448 patients with high-risk or advanced hematologic malignancies given T-replete grafts after myeloablative conditioning. No statistically significant differences were found between recipients of a matched sibling donor (MSD) and 10/10 MUD in survival, disease-free survival (DFS), and nonrelapse mortality (NRM) for patients with high-risk disease or those given bone marrow as a graft source. However, for patients with intermediate-risk disease receiving peripheral blood grafts, we observed higher NRM and lower overall survival (OS) in the 10/10 MUD group compared to the MSD cohort. Graft-versus-host disease (GVHD) was higher in the MUD group compared to the MSD group. These results suggest that if a patient has high-risk disease and an MSD is not available, selection of an HLA-allele-matched MUD may provide similar OS and DFS, and therefore lack of an MSD in and of itself should not preclude such a patient from undergoing transplantation. However, for patients with intermediate-risk disease, transplantation with peripheral blood from a 10/10 MUD is associated with lower survival than an MSD.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447462      PMCID: PMC2934755          DOI: 10.1016/j.bbmt.2010.03.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

1.  Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.

Authors:  Ibrahim Yakoub-Agha; Florence Mesnil; Mathieu Kuentz; Jean Michel Boiron; Norbert Ifrah; Noel Milpied; Sami Chehata; Helene Esperou; Jean-Paul Vernant; Mauricette Michallet; Agnes Buzyn; Nicole Gratecos; Jean Yves Cahn; Jean Henri Bourhis; Zina Chir; Colette Raffoux; Gerard Socié; Jean Louis Golmard; Jean-Pierre Jouet
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

Review 2.  National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.

Authors:  Robert A Bray; Carolyn K Hurley; Naynesh R Kamani; Ann Woolfrey; Carlheinz Müller; Stephen Spellman; Michelle Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

3.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

Authors:  K Wheatley; A K Burnett; A H Goldstone; R G Gray; I M Hann; C J Harrison; J K Rees; R F Stevens; H Walker
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

4.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

5.  Limits of HLA mismatching in unrelated hematopoietic cell transplantation.

Authors:  Effie W Petersdorf; Claudio Anasetti; Paul J Martin; Ted Gooley; Jerald Radich; Mari Malkki; Ann Woolfrey; Anajane Smith; Eric Mickelson; John A Hansen
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Steven Z Pavletic; Claudio Anasetti; A John Barrett; Tao Wang; Dan Wang; Joseph H Antin; Paolo Di Bartolomeo; Brian J Bolwell; Christopher Bredeson; Mitchell S Cairo; Robert P Gale; Vikas Gupta; Theresa Hahn; Gregory A Hale; Jorg Halter; Madan Jagasia; Mark R Litzow; Franco Locatelli; David I Marks; Philip L McCarthy; Morton J Cowan; Effie W Petersdorf; James A Russell; Gary J Schiller; Harry Schouten; Stephen Spellman; Leo F Verdonck; John R Wingard; Mary M Horowitz; Mukta Arora
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

7.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

8.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

Review 9.  Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.

Authors:  Martin Stanulla; Gunnar Cario; Barbara Meissner; André Schrauder; Anja Möricke; Hansjörg Riehm; Martin Schrappe
Journal:  Blood Cells Mol Dis       Date:  2007-05-25       Impact factor: 3.039

10.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

Authors:  C Anasetti; D Amos; P G Beatty; F R Appelbaum; W Bensinger; C D Buckner; R Clift; K Doney; P J Martin; E Mickelson
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

View more
  20 in total

1.  Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.

Authors:  Amir A Toor; Roy T Sabo; Catherine H Roberts; Bonny L Moore; Salman R Salman; Allison F Scalora; May T Aziz; Ali S Shubar Ali; Charles E Hall; Jeremy Meier; Radhika M Thorn; Elaine Wang; Shiyu Song; Kristin Miller; Kathryn Rizzo; William B Clark; John M McCarty; Harold M Chung; Masoud H Manjili; Michael C Neale
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

Review 2.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

3.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

Review 4.  Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.

Authors:  Christopher G Kanakry; Marcos J de Lima; Leo Luznik
Journal:  Semin Hematol       Date:  2015-03-18       Impact factor: 3.851

5.  Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.

Authors:  Wael Saber; Shaun Opie; J Douglas Rizzo; Mei-Jie Zhang; Mary M Horowitz; Jeff Schriber
Journal:  Blood       Date:  2012-02-10       Impact factor: 22.113

6.  Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.

Authors:  Marie Bleakley; Shelly Heimfeld; Keith R Loeb; Lori A Jones; Colette Chaney; Stuart Seropian; Ted A Gooley; Franziska Sommermeyer; Stanley R Riddell; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 7.  Stopping higher-risk myelodysplastic syndrome in its tracks.

Authors:  Daniel A Pollyea; Jonathan A Gutman
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

8.  Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

Authors:  Wael Saber; Corey S Cutler; Ryotaro Nakamura; Mei-Jie Zhang; Ehab Atallah; J Douglas Rizzo; Richard T Maziarz; Jorge Cortes; Matt E Kalaycio; Mary M Horowitz
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

9.  Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker
Journal:  J Allergy Clin Immunol       Date:  2013-10-15       Impact factor: 10.793

10.  In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.

Authors:  C Burt; A Parker; G McQuaker; M Copland; C Brierley; A-M Little; A Clark
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.